The Billroth III guidelines were developed during a consensus meeting of the Austrian Society of Gastroenterology and Hepatology (ÖGGH) and the Austrian Society of Interventional Radiology (ÖGIR) held on 18 February 2017 in Vienna. Based on international guidelines and considering recent landmark studies, the Billroth III recommendations aim to help physicians in guiding diagnostic and therapeutic strategies in patients with portal hypertension.
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Definitions of portal hypertension II. Diagnosis and screening of portal hypertension III. Preprimary prophylaxis and prevention of decompensation IV. Primary prophylaxis of variceal bleeding V.
Acute variceal bleeding VI. Secondary prophylaxis of variceal bleeding VII. Measurement of the hepatic venous pressure gradient (HVPG) VIII. Portal hypertensive gastropathy IX. Gastric varices X.
Management of ascites XI. Spontaneous bacterial peritonitis (SBP)
The strength of the underlying evidence and the recommendations were based on a modified version of the GRADE system (Table 1) I. Definitions of portal hypertension 1 . The term compensated advanced chronic liver disease (cACLD) may be used similar to cirrhosis and is defined as confirmed liver stiffness >15 kPa on transient elastography [2] . Diagnosis of cACLD should trigger screening for clinically significant portal hypertension (CSPH) [3] . (A1) 2. CSPH is defined as an increase of the hepatovenous pressure gradient (HVPG) to values of ≥10 mm Hg. (A1) [3] 3. Normal portal pressure is defined as HVPG of ≤5 mm Hg, while subclinical portal hypertension is defined as HVPG 6-9 mm Hg. (A1) 4. CSPH might already be present in compensated patients (without ascites, without varices). (A1) 5. The presence of gastroesophageal varices (GOVs), variceal hemorrhage, ascites (in the absence of significant cardiac, malignant, peritoneal or renal comorbidities) and/or the presence of large portosystemic collaterals on imaging studies are indicative of the presence of CSPH [3] . (A1) 6. Assessing the four Baveno stages of portal hypertension is clinically useful to quickly assess the prognosis of patients with liver cirrhosis: Baveno-I compensated, no varices, Baveno-II compensated, presence of GOVs, Baveno-III decompensated with ascites and Baveno-IV decompensated, history of variceal bleeding [3, 4] . (B1) 1. Patients with cirrhosis (or cACLD) should be screened for CSPH [3] (see Billroth-III screening algorithm in Fig. 1 ). (A2) 2. After the initial diagnosis of cirrhosis (or cACLD) screening endoscopy may be performed at least once if the patient never had an upper GI endoscopy before. (C1) 3. In cirrhotic patients with a platelet count >150 G/L and liver stiffness <15 kPa on transient elastography screening endoscopy can be safely deferred [5] [6] [7] . (B1) 4. Esophageal varices (EV) should be graded as absent, small (<5 mm of diameter), or large (≥5 mm).
The presence of red spots should be indicated for risk stratification. (A2) 5. Gastric varices should be described as GOV-1 (continued varices on minor curvature), GOV-2 (continued varices on larger curvature extending to the fundus) or isolated gastric varices (IGV-1) isolated fundal varices or IGV-2 ectopic varices in the stomach. The presence of red spots should be indicated for risk stratification [8] . (B2) 6. In patients without varices, endoscopy should be repeated every 2 years in the case of compensated cirrhosis and every year in the case of decompensated cirrhosis [3] . (C1) 7. Patients with low-risk varices should receive nonselective beta blockers (NSBBs). (C1) 8. In compensated patients with varices (EV or GOV)
receiving NSBBs there is no indication for endoscopic monitoring of the varices [3] . (C1) 9. If HVPG is measured as ≥10 mm Hg, endoscopy should be repeated every year in order to screen for the presence of varices, since CSPH is predictive of the formation of esophagogastric varices [3] . (A1) 10. There is no indication for subsequent endoscopic surveillance once large EVs or gastric varices (≥5 mm) are detected, unless endoscopic treatment is performed for primary or secondary prophylaxis of variceal bleeding [3] . (B1)
III. Preprimary prophylaxis and prevention of decompensation
The effectiveness of NSBBs in the setting of preprimary prophylaxis (prevention of the development of varices and variceal bleeding in patients with compensated cirrhosis; cACLD) has been addressed in a landmark study which randomly assigned patients with cirrhosis and portal hypertension (defined by HVPG ≥6 mm Hg; 63% had CSPH) to timolol or placebo [9] . After a median follow-up of nearly 5 years, approximately 40% of patients in both groups met the composite primary endpoint of development of varices or variceal bleeding. Thus, in general, there is no indication for NSBBs treatment in patients who have not developed varices; however, NSBBs might be indicated for extrahepatic comorbidities (e. g. arterial hypertension, coronary heart disease, and heart failure). In the aforementioned study, patients who had a relative HVPG decrease of >10% after 1 year showed a lower incidence of the primary endpoint [9] ; however, relevant HVPG decreases during NSBBs treatment are only observed in patients with CSPH [10] . In a recent randomized controlled trial (RCT) restricted to patients with CSPH, preprimary prophylaxis (44%) or small varices without red spot signs (56%), propranolol/carvedilol decreased the risk of S136 Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III)
K original article hepatic decompensation, mostly by decreasing the incidence of ascites [11] . Thus, future studies should address the potential benefits of early initiation of NSBBs (especially carvedilol) treatment in the subgroup of patients with CSPH.
1. Preprimary prophylaxis defines the prevention of the development of varices and variceal bleeding in patients with compensated cirrhosis (cACLD) who do not have varices. (A1) 2. In general, there is no indication for NSBBs treatment in patients with cACLD who have not yet developed varices. Nevertheless, NSBBs might be indicated for extrahepatic comorbidities (e. g. arterial hypertension, coronary heart disease, and heart failure). (A1) 3. Preprimary prophylaxis with NSBBs can be considered in patients with CSPH since it may reduce the risk of developing ascites. (B2)
IV. Primary prophylaxis of variceal bleeding

Indications for primary prophylaxis
This chapter addresses primary prophylaxis in patients with esophageal varices (EV) and recommendations for the management of gastric varices is discussed in Chap. IX (gastric varices).
1. All patients with large EV (≥5 mm) should be treated either with NSBBs or with endoscopic variceal band ligation (EVL). The choice of treatment should be based on patient preference and characteristics as well as local resources and expertise. (A1)
Choice of treatment for primary prophylaxis 2. Patients with small EVs with risk factors (red spot signs and/or with decompensated cirrhosis ChildPugh class B or C) should receive NSBBs since they reduce the risk of bleeding in this setting [12] . (A1) 3. Patients with small EV without risk factors should also receive NSBBs prophylaxis, since NSBBs may reduce the incidence of variceal bleeding in this setting. (C1) 4. If monitoring of HVPG is available, treatment with NSBBs should be preferred, since achieving a hemodynamic response defines an excellent long-term prognosis [13] . (B1) 5. Hemodynamic response to NSBBs is defined as a reduction in HVPG ≤ 12 mm Hg or at least ≥10% from baseline. This is not only associated with a lower risk of first variceal bleeding but also with a lower incidence of ascites and death [14] [15] [16] . (A1) 6. The lack of access to HVPG measurement should not prevent physicians from using NSBBs for primary prophylaxis, since bleeding rates in primary prophylaxis are low even in hemodynamic nonresponders to NSBBs. (B1)
7. Propranolol or carvedilol should be used for prophylactic pharmacological treatment of patients with varices. Carvedilol is more effective than propranolol in primary prophylaxis of variceal bleeding [17, 18] . (B1) 8. In patients with contraindications to NSBBs therapy, NSBBs intolerance, non-adherence to NSBBs or non-responders to NSBBs, EVL should be used.
Endoscopic treatment 9 . Use of EVL in primary prophylaxis should be performed in 2-6-week intervals until variceal eradication. A first follow-up endoscopy after variceal eradication should be performed after 6 months and then every 12 months. If EVL must be restarted the intervals are similar to first EVL [19] . (B1)
Pharmacological treatment with NSBBs
10. There is no need for follow-up endoscopy in patients on pharmacological therapy. (B1) 11. The initial dose of propranolol is 20-40 mg twice daily with a maximum dosage of 160 mg/day in patients without and 80 mg/day with ascites. The initial dose of carvedilol is 6.25 mg once daily with a maximum dosage of 12.5 mg/day [16] . (B1) 12. The dose of NSBBs should be increased to achieve a resting heart rate of 55-60 beats per minute (bpm). The systolic blood pressure should not decrease below 90 mm Hg. (B1) 13. There is no relationship between reduction in portal pressure or protection from variceal bleeding and the reduction in resting heart rate or in blood pressure. There is no consensus on whether NSBBs treatment should be continued in patients without a hemodynamic response to NSBBs treatment; however, the benefit of NSBBs treatment may go beyond the portal pressure reducing effect and may also reduce the incidence of ascites, infections, decompensation and death [14, 15] . (B1) 14. In patients with severe or refractory ascites NSBBs should be discontinued during spontaneous bacterial peritonitis (SBP), a decline of systolic blood pressure <90 mm Hg or hyponatremia Na < 125 mmol/l or in the presence of acute kidney injury [20] [21] [22] . (C2) 15. Isosorbide mononitrate (ISMN) (alone or combined with NSBBs) is not recommended for primary prophylaxis, since it is not more effective in preventing first bleeding but increases side effects [23, 24] . (B1) 16. The combination of endoscopic treatment and NSBBs treatment does not further decrease the incidence of bleeding or death but is associated
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Early rebleeding <5days
Rebleeding/failure with a higher number of side effects and cannot be recommended for primary prophylaxis [25] . (A1) 17. The presence of varices does not represent an indication for proton pump inhibitors (PPIs); however, a short course of PPI post-variceal ligation reduces ulcer size and early bleeding risk [26, 27] . (C1) 18. Transjugular intrahepatic portosystemic shunt (TIPS) placement is not recommended for prevention of first variceal hemorrhage [28] . (C1)
Secondary prophylaxis
V. Acute variceal bleeding
The Billroth-III algorithm for treatment of acute variceal bleeding is summarized in Fig. 2 Definition 1. Acute variceal bleeding (AVB) is diagnosed in cases of: (a) active bleeding at endoscopy or (b) signs of upper GI bleeding (hematemesis, blood or coagulated blood, melena) in patients with varices in the absence of any other source of bleeding.
Blood products
2. Blood volume restitution should be done conservatively using packed red cells to maintain a Hb level of 7-8 g/dl (unless comorbidities/active bleeding necessitate more aggressive substitution), and substitution of fluids to maintain hemodynamic stability [29] . 16 . Endoscopic treatment should be performed as soon as possible after hemodynamic stabilization (at the latest 12 h after admission and ideally during the first 6 h), especially in patients with clinically significant bleeding or in patients with suspected cirrhosis. The therapeutic algorithm for AVB is summarized in Fig. 2 NSBBs should be discontinued during SBP, a decline of systolic blood pressure <90 mm Hg or hyponatremia Na < 125 mmol/L or in cases of acute kidney injury (AKI).
Endoscopic therapy
VII. Measurement of hepatic venous pressure gradient (HVPG)
1. Portal pressure, assessed by the hepatic venous pressure gradient (HVPG) drives the development of liver-related complications and mortality in patients with (compensated) advanced chronic liver disease (cACLD) [38, 39] . (A1) 2. HVPG measurements are indicated for assessing the prognosis and monitoring the response to etiologic and HVPG-lowering treatment [38, 39] . (A2) 3. The number needed to treat (NNT) for NSBBs for preventing variceal bleeding ranges from 5 (secondary prophylaxis) to 10 (primary prophylaxis) [40] , underlining the need for methods to assess the expected benefits of NSBBs treatment in the individual patient [21] . (B2) 4. HVPG response is the only established surrogate for the effectiveness of NSBBs in preventing (recurrent) variceal bleeding. If HVPG decreases to a value of <12 mm Hg or is reduced by ≥20% during NSBBs treatment, patients are protected from variceal bleeding and survival is increased [41, 42] .
(A1) 5. The assessment of acute HVPG response to intravenous propranolol (0.15 mg/kg given as 15 min infusion) provides a valuable alternative to chronic response assessment (separate measurements). An HVPG reduction by >10% or to <12 mm Hg (measured after the 15 min infusion) is sufficient in the acute setting [14, 43] . (A1) 6. Several studies support the use of HVPG-guided therapy. Thus, in centers with sufficient experience, HVPG response should be assessed to guide treatment decisions [11, 16, [44] [45] [46] [47] . (A2) 7. HVPG measurements should be performed in fasting conditions. Since the procedure is generally well tolerated [48] , ideally no sedation, or if necessary only low doses of midazolam (maximum 0.02 mg/kg) should be used [49, 50] . (A1) 8. HVPG measurements should be performed using a balloon catheter ensuring a sufficient wedge position and in order to maximize the assessed amount of liver parenchyma [51] [52] [53] . (A1) 9. Free hepatic venous pressure (FHVP) should be measured in a liver vein 2 cm from the inferior vena cava (stable values are usually obtained after 15 s) [54] . A difference between the inferior vena S140 Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III) VIII. Portal hypertensive gastropathy 1 . Portal hypertensive gastropathy (PHG) is defined as a macroscopically visible mosaic-like pattern of the gastric mucosa (usually fundus or corpus) and can be found in 35-80% of cirrhotic patients, correlates with the Child-Pugh score and the degree of portal hypertension (PHT) [55] . A summary for the management of PHT is shown in Fig. 3 . (A1) 2. PHG should be differentiated into mild PHG (without signs of bleeding) and severe PHG (red marks or active bleeding). (A1) 3. Gastric antral vascular ectasia (GAVE) is a distinct entity that is endoscopically characterized by tortuous columns of erythematous (mild) or hemorrhagic (severe) lesions in a "watermelon" or diffuse pattern (in the latter case histology may help to confirm diagnosis). GAVE may be present without cirrhosis and is associated with PHT in only 30% of cases [56] . (A1) 4. The incidence of acute PHG bleeding is 2-20% (mostly in severe PHG) [57] . (B2) 5. The incidence of chronic PHG bleeding is around 3-26% and is defined by a >2 g/dl decrease in Hb or by the presence of anemia together with positive faecal occult blood tests [57] . [86] . The same is true for angiotensin receptor blockers and angiotensin converting enzyme inhibitors [87, 88] . Aminoglycosides should only be used in cases where infections cannot be otherwise treated [89, 90] . (A1) 20. In the absence of strong indications, proton pump inhibitors (PPIs) should not be used in patients with ascites since PPIs might be associated with a higher risk of infections [91] . (A2) 21. Ascites per se is not a contraindication for NSBBs, but they should be used with caution. Carvedilol should not be used in patients with severe or refractory ascites due to induction of hypotension [92] . In patients with severe or refractory ascites, high doses of propranolol (>80 mg/day) should be avoided [93] . (C2)
Refractory ascites
Only less than 10% of patients with cirrhosis and ascites are refractory to treatment regimens consisting of sodium restriction and oral diuretics [94] . 
Refractory ascites is defined by the International
XI. Spontaneous bacterial peritonitis (SBP)
1. All patients presenting with ascites for the first time, with recurrence of ascites, or deterioration of ascites, evidence of systemic infection, GI bleeding, worsening liver or renal function, or hepatic encephalopathy should undergo paracentesis to screen for SBP [97] . (A1) 2. Ascitic fluid and blood cultures should be performed using blood culture bottles. Even in culture-negative SBP, positive blood cultures might hint at the responsible organism [97] . (A1) 3. In patients with an ascitic fluid absolute neutrophil count >250/µl or a positive ascitic fluid culture, antibiotic therapy with gram-negative coverage (e. g. aminopenicillin/beta-lactamase inhibitor, third generation cephalosporin, or quinolone) should be started immediately. (A1) 4. Chinolones should not be used to treat SBP in patients who were on norfloxacin prophylaxis [97] . (B1) 5. In selected high-risk patients (e. g. nosocomial SBP as defined by onset of signs and symptoms of infection after 72 h from hospitalization and/or patients with sepsis), the use of combination regimens as initial therapy might be warranted [113] . (A2) 6. To prevent the development of hepatorenal syndrome (HRS) type of AKI, 1.5 g/kg bodyweight albumin should be administered in patients with SBP at the time of diagnosis, plus 1 g/kg body weight on day three [114] . (A1) 7. Blood pressure should be carefully monitored in patients with SBP and NSBBs should be discontinued in the case of systolic blood pressure <90 mm Hg, hyponatremia Na < 125 mmol/L, or AKI [21, 22] . (C2) 8. In the case of an ascitic fluid neutrophil count <250/µL but clinical evidence of infection, similar antibiotic therapy should be initiated and continued until culture results are available [97] . (B1) 9. A second paracentesis should be performed 48 h after initiation of the antibiotic therapy to demonstrate a decrease of the ascitic absolute neutrophil count by 25% of the initial value [115] . (A1) 10. A smaller drop is highly suggestive of failure of the antibiotic regimen. In these patients, antibiotic therapy should be adopted based on culture results and susceptibility testing [97] . (A1) 11. If culture-negative, antibiotic therapy should be changed to cover gaps in the antibacterial spectrum of the initial therapy, as well as relevant multidrug-resistant gram-negative and gram-positive bacteria (e. g. meropenem plus daptomycin) [113] . (B1) 12. Due to the poor prognosis of patients who recovered from SBP, liver transplantation should be considered in these patients [97] . (A1) 13. All patients with a history of SPB should be treated continuously with secondary prophylaxis using norfloxacin 400 mg/day or alternatively co-trimoxazole (800 mg/160 mg/day) [97] . (A1) 
XII. Management of acute kidney injury and hepatorenal syndrome (HRS-AKI)
Acute kidney injury (AKI) is a common complication of cirrhosis with a significant prognostic impact [125, 126] . As a consequence of systemic and splanchnic arterial vasodilatation, renal perfusion is critical in patients with advanced cirrhosis and CSPH [127] . AKI is commonly triggered by precipitating events leading to further circulatory compromise including overdose of diuretics, large volume paracentesis without albumin replacement, GI blood loss, and infections (e. g. SBP) [128] .
Diagnosis and definitions
The traditional diagnostic criteria of renal failure in cirrhosis (percentage increase in sCr, ≥50% to a final value ≥1.5 mg/dl) [129] were replaced by the Kidney Disease Improving Global Outcome (KDIGO) criteria to diagnose AKI [130] and adapted for patients with cirrhosis by the International Club of Ascites (ICA) in 2015 [131] . One of the main modifications of the ICA-AKI criteria is the abandonment of a threshold of sCr ≥
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A detailed algorithm for diagnosis and treatment of AKI in patients with cirrhosis is shown in Fig. 4 .
Diagnosis and definitions
1. AKI in cirrhosis should be diagnosed according to the ICA-AKI criteria [131] . (B1): -Increase in sCr ≥ 0.3 mg/dl within 48 h or -Increase in sCr ≥ 50% from a baseline value that is known or presumed to have occurred in the past 7 days.
-A baseline sCr value obtained in the previous 3 months should be used. If no previous sCr value is available, the sCr on admission should be used. In cases of impairment of renal function (sCr ≥ 1.5 mg/dl) at time of admission and a clearly identifiable precipitating event, it is reasonable to assume AKI based on clinical judgement. -The use of a reduction in urine output as part of the diagnostic criteria was eliminated in the new ICA criteria for the diagnosis of AKI because many patients with cirrhosis and ascites are oliguric as part of the sodium and water retention syndrome and yet maintain a nearly normal GFR [131, 134] . aminoglycosides, contrast media) -Exclusion of parenchymal kidney disease (proteinuria <500 mg/day, <50 red blood cells per high power field, normal renal ultrasound) 4. Hepatorenal syndrome type 2 is defined as slowly progressive impairment of renal function (sCr > 1.5 mg/dl) [135, 136] fulfilling the abovementioned diagnostic criteria of HRS-AKI and is usually associated with refractory ascites [125, 126] (A1).
Management of AKI and HRS-AKI in cirrhosis
The initial management of AKI should focus on identification and correction of precipitating factors that further exaggerate the already disturbed hemodynamics in advanced cirrhosis [131, 137, 138] .
5. The following measures should be taken in cirrhotic patients with initial ICA-AKI stage 1. (A1) -Review of all medications (including over the counter drugs) -Reduction or withdrawal of diuretic therapy and/ or lactulose for patients who are volume-depleted from diuretics or excess lactulose use -Withdrawal of all potentially nephrotoxic agents (e. g. NSAIDs) -Careful assessment of ongoing use of drugs potentially inducing/aggravating hypotension (e. g. NSBBs) [93, 139] -Plasma volume expansion with crystalloids or albumin in patients with clinically suspected hypovolemia -Blood transfusion in patients with AKI after GI blood loss -Screening for bacterial infections (e. g. SBP) and early or empiric antibiotic treatment if an infection is diagnosed or strongly suspected [140] 6. In the case of response (return of sCr to a value within 0.3 mg/dl of the baseline value), patients should be followed closely for early identification of potential new episodes of AKI [131, 141] . (B2) -Assessment of sCr every 2-4 days during hospitalization -Assessment of sCr every 2-4 weeks during the first 6 months after discharge 7. In the case of stage 2 or 3 ICA-AKI or progression of stage 1 ICA-AKI to a higher stage, patients need to be assessed for the presence of HRS-AKI in addition to the following measures [131] . (B1): -Administration of the same general measures as described for patients with ICA-AKI stage 1, -Withdrawal of diuretics if not withdrawn already, -Plasma volume expansion with albumin for two consecutive days (1 g/kg body weight, maximum 100 g/day). original article 17 . Patients should be monitored for hyponatremia, which more commonly occurs in patients with less advanced liver disease and (near) normal baseline serum sodium levels [146] . (A1). 18. Continuous infusion (initial dose of 2 mg/day; maximum 12 mg/day) decreases the rate of adverse events, the mean effective terlipressin dose and, thus, might also decrease costs as compared to bolus administration (initial dose of 0.5 mg every 4 h; maximum 2 mg every 4 h). Continuous infusion might be preferred over bolus administration [147] . (A1) 19. Although terlipressin has been consistently shown to improve renal function, its impact on survival is less clear [148] . (A1) 20. Terlipressin is particularly beneficial in patients with systemic inflammatory response or sepsis and might also prevent variceal bleeding during the period of discontinuation of NSBBs [149] . (B2) Norepinephrine 21 . Norepinephrine (initial dose of 0.5 mg/h; maximum dose studied in RCTs: 3 mg/h) is an equally effective and inexpensive alternative to terlipressin [150] .
Treatment of HRS-AKI
(A1)
Response to treatment and considerations for follow-up 
